Close menu




August 25th, 2021 | 13:25 CEST

BioNTech, Kainantu Resources, QIAGEN - A threatening development

  • Mining
Photo credits: pixabay.com

Most recently, with the appearance of the highly infectious Delta variant, it is clear that the Corona pandemic is not over. Infection numbers are rising, and the fourth wave has reached Germany. To better prepare for the growing number of cases this fall and avoid another hard lockdown, policymakers are relying on greater use of Corona testing in addition to vaccination programs. The higher demand for testing, also considering the start of the new school year, is again making the coffers of diagnostics companies ring.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , Kainantu Resources Ltd. | CA48301H1073 , QIAGEN NV EO -_01 | NL0012169213

Table of contents:


    Rising demand

    Among other PCR and rapid tests manufacturers, the biotechnology and diagnostics Company QIAGEN is benefiting from the worrying trend. Overall, test manufacturers recently shipped more than twice as many PCR tests to the US as they did in mid-June, QIAGEN CEO Thierry Bernard said Tuesday in an interview with Bloomberg news agency. He added that demand is also rising enormously in other countries like Israel, France, Italy, and Spain.

    After growth prospects were only recently downgraded by growing vaccine advances, additional orders are coming onto the books due to the highly contagious Delta variant. However, he said the future course of demand for the PCR tests is difficult to gauge. From a technical perspective, QIAGEN's stock is on the verge of breaking out and climbing to a new all-time high. Investors should remain invested and tighten the stop.

    Onward, ever onward

    Without a doubt, vaccine manufacturers such as Moderna or BioNTech are the winners of the crisis. And even at dizzying valuation levels, the shares are being bought up after short, volatile setbacks. After a correction in the share price from over USD 450 to USD 325, BioNTech is once again preparing to overcome the USD 400 mark.

    The Mainz-based Company benefited from a decision by the US Food and Drug Administration (FDA), which, together with partner Pfizer, was the first Company in the US to receive regular approval for a Corona vaccine. "The FDA's approval of this vaccine is a milestone in the fight against the COVID-19 pandemic," said acting FDA Commissioner Janet Woodcock. Despite this positive news, the valuations of BioNTech at EUR 79 billion and Moderna at as much as USD 142 billion are extremely inflated.

    Delta puts the brakes on

    With the economy recovering and inflation on the rise, calls for central banks to end unlimited bond purchases and bring forward interest rate hikes have been heard more frequently in recent weeks. But the delta variant supports FED Chairman Jerome Powell's cautious strategy. He sees the economy's recovery after the global lockdowns as temporary and wants to continue to adhere to the loose monetary policy. There are already signs of an economic slowdown, so the timing of tapering is unlikely to be pushed further forward. Low interest rates and high inflation are the best conditions for a resurgent gold price. In the long term, high government debt levels mean that there is probably little to be gained from investing in gold or gold mining stocks.

    First-class network

    Promising commodity projects with a focus on gold and copper are in the portfolio of the Canadian mining company Kainantu Resources. Geographically, the focus is on the Asia-Pacific island nation of Papua New Guinea (PNG). The government supports the mining and oil and gas industries so that gold, copper, nickel mining, and crude oil and gas production contribute about 85% of the gross domestic product. Favorable mining laws, similar to Australia's, have recently allowed industry giants such as Exxon Mobil and TOTAL to set up operations in the world's third-largest island nation.

    In addition to Barrick Gold and Newcrest Mining, the Kainantu mine, operated by K92 Mining, is one of the highest-grade deposits in PNG, and last year it had the fourth-highest production rate in the world. Close to the K92 Mine, Kainantu Resources has two prospective projects. KRL South and KRL North hold the potential to host high-grade epithermal and porphyry mineralization similar to that found in the region. KRL South covers 597 square meters and is located in the Eastern Highlands province, approximately 30 kilometers from the mine of K92. The project is located in an unexplored area separated by the Kainantu fault line in the middle. KRL North is smaller at 129 sq m, located on the central Bilimoia mineral field and directly adjacent to K92. In addition, the May River Project was recently acquired, adjacent to one of the world's largest undeveloped copper resources at Freida River.

    Cooperation with Asia Pacific Energy Ventures and collaboration with stakeholders at all levels provides Kainantu Resources access to world-class deposits in the island nation. The Canadian Company aims to build a high-quality Asia Pacific junior gold mining company in the long term. With a market capitalization of CAD 10 million, the Company has plenty of imagination.

    You can read an in-depth interview with Kainantu Resources CEO Matthew Salthouse here.


    The fourth wave is rolling towards Germany. In addition to vaccine producers, manufacturers of PCR and rapid tests such as QIAGEN are the primary beneficiaries. Due to the Delta variant, there could be a renewed weakening of the economy; interest rate hikes are therefore not expected. High inflation and low-interest rates are the best conditions to invest in gold mining stocks. Here, one should observe the share of Kainantu Resources.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Fabian Lorenz on June 29th, 2022 | 12:18 CEST

    Buy or sell? Nel, Zalando, Aspermont under analyst review

    • Commodities
    • Investments
    • Hydrogen
    • Mining

    After the heavy losses of the past months, a countermovement seems to be starting at the moment. Whether this will turn into a real summer rally remains to be seen. Buy or sell is the question. Analysts see a price potential of over 50% for Nel ASA. Even though competition from China and India is increasing. Aspermont also appears attractive at the current price level. The latest quarterly figures were positive, and the positioning of the small-cap in the booming commodities sector is promising. At Zalando, analysts react to the profit warning, and the price targets are significantly reduced. Nevertheless, some advise buying the online fashion retailer, but not everyone.

    Read

    Commented by Nico Popp on June 14th, 2022 | 12:26 CEST

    Unheeded crisis signals! What is next: BioNTech, Lufthansa, Triumph Gold

    • Biotechnology
    • travel
    • Gold
    • Mining

    There are always comeback stocks on the stock market. The airports are full of travellers who are being drawn to distant countries. So the tourism industry, and airlines too, could almost strap themselves in for a comeback. If only it weren't for the new BA.5 virus variant, which has infected large parts of the population in Portugal within a very short time. It seems investors have to choose between travel stocks and pandemic stocks when looking for comeback stocks - or is there a laughing third party?

    Read

    Commented by Nico Popp on June 14th, 2022 | 11:06 CEST

    These are the stocks where the action is: TUI, Globex Mining, Varta

    • travel
    • Commodities
    • Mining

    Which stocks are hot right now? These days we are experiencing a real boost in many areas. People are rushing outside, flocking to festivals and flying off on vacation again. The normality of 2019 may just be good enough for the 2022 vacation season. But initial warnings of a pandemic comeback are unsettling investors. We present three stocks from different sectors and explain why they could be booming right now.

    Read